Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) and Sarepta Therapeutics (SRPT – Research Report).
Roche Holding AG (RHHVF)
Berenberg Bank analyst Luisa Hector maintained a Hold rating on Roche Holding AG today and set a price target of CHF265.00. The company’s shares closed last Friday at $255.06, close to its 52-week low of $252.87.
According to TipRanks.com, Hector is ranked #2300 out of 8727 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $301.89 average price target, which is a 16.4% upside from current levels. In a report issued on February 5, UBS also maintained a Hold rating on the stock with a CHF248.00 price target.
See today’s best-performing stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
Wedbush analyst Andreas Argyrides maintained a Buy rating on Sarepta Therapeutics today and set a price target of $224.00. The company’s shares closed last Friday at $134.61.
According to TipRanks.com, Argyrides is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $160.33, which is a 14.5% upside from current levels. In a report issued on February 5, Citi also maintained a Buy rating on the stock with a $160.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- Roche price target lowered to CHF 250 from CHF 260 at Morgan Stanley
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
- Genentech’s Xolair approved by FDA for children, adults with food allergies
- Roche enters collaboration agreement with PathAI to develop pathology algorithms
- Repare Therapeutics to regain global rights to Camonsertib
